Health
OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients
Alnylam Canada ULC is pleased to announce that OXLUMO® (lumasiran) is now funded across Canada through both public and private plans. OXLUMO is an RNA interference (RNAi) therapeutic administered via subcutaneous injection, indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in paediatric and adult patients.1
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1","length":107,"tagName":"p","attribs":{}},{"type":"text","content":"MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC is pleased to announce that OXLUMO® (lumasiran) is now funded across Canada through both public and private plans. OXLUMO is an RNA interference (RNAi) therapeutic administered via subcutaneous injection, indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in paediatric and adult patients.1","length":399,"tagName":"p"},{"type":"image","alt":"Alnylam Pharmaceuticals, Inc. (CNW Group/Alnylam Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"Alnylam Pharmaceuticals, Inc. (CNW Group/Alnylam Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":210,"url":"https://media.zenfs.com/en/cnwgroup.com/e55ccc485ee813ed86dfd2983ae58bee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DvWgkfuXU1v2XlKoCoQTGg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM3MDtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/e55ccc485ee813ed86dfd2983ae58bee","width":400,"height":210}},"href":"https://mma.prnewswire.com/media/2720273/Alnylam_Pharmaceuticals__Inc__OXLUMO___lumasiran_injection__Now.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"OXLUMO is the first therapy for PH1 approved in Canada, and among the first medications to be included on the common list of new drugs for rare diseases, as part of the Government of Canada's National Strategy for Drugs for Rare Diseases. The common list was developed to help patients with rare diseases have access to treatments as early as possible.","length":356,"tagName":"p"},{"type":"text","content":"PH1 is an ultra-rare and debilitating genetic disease of the liver characterized by oxalate overproduction.2 Oxalate is an end-product of metabolism and high levels of it are toxic because it cannot be broken down by the human body. Oxalate overproduction results in the deposition of calcium oxalate crystals in the kidneys and urinary tract and can lead to the formation of painful and recurrent kidney stones, nephrocalcinosis (renal deposition of calcium oxalate crystals), progression to kidney failure, and systemic organ dysfunction.2","length":541,"tag...